Welcome to LookChem.com Sign In|Join Free
  • or
METHYL 3-(5-BROMOPYRIDIN-2-YL)-2-(TERT-BUTOXYCARBONYL)PROPANOATE is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

656801-27-3

Post Buying Request

656801-27-3 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

656801-27-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 656801-27-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,5,6,8,0 and 1 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 656801-27:
(8*6)+(7*5)+(6*6)+(5*8)+(4*0)+(3*1)+(2*2)+(1*7)=173
173 % 10 = 3
So 656801-27-3 is a valid CAS Registry Number.

656801-27-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 13, 2017

Revision Date: Aug 13, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-O-tert-butyl 1-O-methyl 2-[(5-bromopyridin-2-yl)methyl]propanedioate

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:656801-27-3 SDS

656801-27-3Relevant academic research and scientific papers

PHOSPHOHISTIDINE AND PHOSPHOTYROSINE ANALOGUES

-

Page/Page column 36; 37, (2015/03/28)

The invention relates to phosphohistidine analogues. The invention also relates to antibodies that specifically bind to the analogues and methods of generating said antibodies. In one embodiment of the invention there is provided a phosphohistidine analogue of Formula V: (V) wherein W is selected from H, CO2H or CONH2; and X is selected from CH or N.

SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF

-

Paragraph 0587-0588; 0635-0636, (2015/02/25)

Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

Synthesis and in vitro evaluation of 18F labeled tyrosine derivatives as potential positron emission tomography (PET) imaging agents

Wang, Limin,Qu, Wenchao,Lieberman, Brian,Ploessl, Karl,Kung, Hank F.

scheme or table, p. 3482 - 3485 (2010/08/22)

Three new 18F labeled fluoroalkyl tyrosine derivatives, O-(2-[18F]fluoroethyl)-α-methyltyrosine (FEMT, [ 18F]2), O-(2-[18F]fluoroethyl)-2-l-azatyrosine (FEAT, [18F]3), O-(2-[18F]fluoroethyl

Efficient large-scale synthesis of Boc-L-azatyrosine

Germain, Herve,Harris, Craig S.,Renaud, Fabrice,Warin, Nicolas

experimental part, p. 523 - 530 (2009/06/20)

A rapid and convenient process for the synthesis of Boc-L-azatyrosine is described from commercially available Boc-β-iodo-Ala-OMe. Copyright Taylor & Francis Group, LLC.

L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS

-

Page/Page column 149-151, (2008/12/07)

The present invention relates to compounds of the formula (I) that inhibit of a5bl function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufac

L-ALANINE DERIVATIVES

-

Page/Page column 86, (2008/06/13)

The present invention relates to compounds that inhibit of a5b1 function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases that have a significant angiogenesis or vascular component such as for treatment of solid tumours. The present invention also relates to compounds that inhibit a5b1 and also that exhibit appropriate selectivity profile(s) against other integrins.

Preparation of enantiomerically pure pyridyl amino acids from serine.

Tabanella, Stefania,Valancogne, Ingrid,Jackson, Richard F W

, p. 4254 - 4261 (2007/10/03)

A range of substituted pyridyl amino acids have been prepared by palladium catalysed cross-coupling of serine-derived organozinc reagents with differently substituted halopyridines. Following this procedure a DMAP analogue has been synthesised and used as

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 656801-27-3